T he time course of absolute myocardial ischemia is rapid. With the interruption of blood flow to the myocardium, aerobic metabolism ceases within 10 seconds,1 and soon even anaerobic metabolism is inhibited due to the accumulation of H', lactate, and other metabolites. To sible but has enough perfusion that cellular integrity can be maintained chronically through low-level aerobic metabolism and the anaerobic consumption of glucose.4 This is the basis for the`8FDG positron emission tomography scan, which demonstrates regions of abnormal glucose metabolism, rather than the more usual lipid metabolism.S A key feature of hibernating myocardium is that its energy production and contractile apparatus are not damaged, only downregulated, so that with restoration of normal perfusion, there is return of systolic contraction.6 Stunned myocardium, by contrast, is that which has undergone an ischemic insult but currently has adequate perfusion. It reflects a period of systolic dysfunction while the myocardium is recovering from the ischemic insult. Stunning undoubtedly is multifactorial but appears to be due in part to cytosolic calcium overload and free radical injury.7 Although this simplistic classification has many exceptions and a large gray zone between the two syndromes, it is a useful distinction conceptually, as hibernating myocardium typically will improve with myocardial revascularization (and not without it), whereas stunned but adequately perfused myocardium may be expected to improve spontaneously. For either condition, however, it is critical that reliable diagnostic methods be available to demonstrate the possibility of recovery of function; for hibernation, such evidence will indicate a need for angioplasty or coronary artery bypass graft surgery; for stunning, evidence of viability is critical in assessing a patient's prognosis after myocardial infarction.
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Results of the Current Study In this issue of Circulation, Smart and colleagues8 have used dobutamine echocardiography in an attempt to define reversibly damaged myocardium in patients after thrombolytic therapy. From a potential population of 121 patients undergoing thrombolytic therapy at their hospital, 63 patients underwent echocardiographic examination during dobutamine infusion within 7 days of the index infarct. Studies were obtained at baseline, at extremely low-dose infusions of dobutamine (4 ,jg. kg1. min-') and at two higher doses (14 to 40 ,gg kg1. min-1), and the data were stored digitally, allowing simultaneous semiquantitative assessment of wall motion at varying dobutamine doses. These dobutamine echos were compared with wall motion obtained on a follow-up echo 4 or more weeks after the infarct.
Not surprisingly, the patients who had improved wall motion on the follow-up study were more likely to have had non-Q-wave infarctions with a low level of creatine prediction of long-term recovery by a number of traditional indexes: the duration of chest pain before thrombolytic therapy; the signs of early reperfusion on clinical, electrocardiographic, or enzymatic grounds; or the status of the infarct related artery at early angiographic follow-up. The single best predictor of late improvement in regional wall motion in this study was the response of the infarct zone myocardium to the infusion of dobutamine. The presence of wall motion enhancement with low-dose dobutamine predicted with 86% certainty the recovery of function on the follow-up echo, whereas absence of improvement with low-dose dobutamine predicted with 90% certainty those patients whose wall motion would remain stable.
There are a number of intriguing points in the results of this study. For instance, more than half of the patients who responded to dobutamine at low dose showed a deterioration in wall motion at intermediateand high-dose dobutamine, and all of these patients had more than 70% residual stenosis in the infarct-related vessel. The combination of enhancement at low-dose dobutamine infusion with deterioration at high dose, comprising 20% of the patients in the current study, thus identifies a patient population with clearly viable myocardium but with low threshold ischemia, for whom revascularization should be considered. Three other patients enhanced at low-dose dobutamine but showed no improvement at late follow-up. All had severe stenoses in their infarct-related vessel, and one may speculate that blood flow was so low that myocardial hibernation was present chronically.
Study Limitations
Despite the very encouraging results of this study, a few caveats are appropriate. First, it represents the experience of a single medical center with a relatively small number of patients. Also, the improvement of wall motion by echocardiography at 4-week follow-up was used as the gold standard for judging the predictive accuracy of the dobutamine echo, rather than an independent standard such as`8FDG positron emission tomography.
Furthermore, the changes in regional wall motion identified in this study were often quite subtle (hypokinetic tissue becoming more normal or akinetic tissue developing hypokinesis), requiring both sophisticated digital processing and highly expert interpretation. The authors of this study largely developed the field of stress echocardiography9 and have an enormous experience in the analysis of digital echocardiographic loops. They were quite meticulous in their assessment of interobserver and intraobserver variability to demonstrate the reliability of the echo readings, but even with this care, there was some disagreement in 5% to 10% of studies. It is unrealistic for the average echocardiographer to expect to achieve these results, unless he or she has the discipline to ensure accurate interpretation of regional wall motion.
Another difficulty with this technique is the extremely fleeting nature of the improved wall motion in some patients. That In still other patients, particularly those with compromised ventricular function, the more pressing question is viability of hypofunctional myocardium, best assessed with positron emission tomography scanning or lowdose dobutamine echocardiography. It should be recognized that neither approach will make the important distinction between stunning and hibernation; demonstrating hibernation has therapeutic implications, whereas the presence of stunned myocardium primarily has prognostic implications for spontaneous recovery.
To date, dobutamine echocardiography has been prospectively compared with positron emission tomography metabolic and perfusion imaging in only a limited way.13 However, if findings are found to be generally concordant, dobutamine echocardiography clearly would be a more cost-effective approach to the assessment of viability, costing less than half of a comprehensive positron scan. In considering these sophisticated imaging techniques, however, one must be careful not to neglect highly predictive data available clinically on all infarction patients. For example, findings from the current study coupled with a previous one with scintigraphic evaluation'4 underscore the value of the peak creatine phosphokinase-MB for a rapid, economical, and seemingly precise method for estimating provocable ischemia and viability. Comparing the different techniques for objective assessment of viability clearly will be an important direction for future investigation. In the meantime, the combination of pharmacological inotropic stimulation and quantitative echocardiography provides a promising strategy for use in selected patients after reperfusion therapy.
